-
JP Morgan Raises PT On Pharmasset To $200
Tuesday, May 24, 2011 - 5:55am | 26JP Morgan has raised the price target on Pharmasset (NASDAQ: VRUS) From $100 to $200 and maintains its Overweight rating.
-
Options Brief: BioSante Pharmaceuticals
Monday, May 23, 2011 - 3:00pm | 72Shares of BioSante Pharmaceuticals (NYSE: BPAX) are higher on the session by 8.37%, trading at $2.85. Overall call volume is now running at 2.05x the daily average, with 66% of all calls traded being purchases on the offer. 4,499 contracts have traded on the session so far. BioSante...
-
Regeneron Pharmaceuticals Announces FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
Monday, May 23, 2011 - 12:14pm | 94Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the U.S. Food and Drug Administration has informed the company that it has scheduled a Dermatologic and Ophthalmic Drugs Advisory Committee Meeting to be held on June 17, 2011 to discuss the Company's Biologics License Application...
-
Researchers to Present Nine Studies on Soliris in Patients with PNH and aHUS at EHA Congress on June9-12
Monday, May 23, 2011 - 11:50am | 130Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that researchers will present data relating to Soliris at the 16th Congress of the European Hematology Association, to be held June 9-12, 2011, in London. Findings will be presented from studies of Soliris as a treatment for patients with...
-
Nasdaq Winners (GMCR, DNDN)
Monday, May 23, 2011 - 10:47am | 56The Nasdaq is getting slammed on Monday, falling around 1.64% to 2,757.33. Among the better performers in today's very weak market are Green Mountain Coffee Roasters (NASDAQ: GMCR) and Dendreon (NASDAQ: DNDN). Green Mountain shares have added 1.80% to $78.06. Dendreon has gained 1.21% to $39.45.
-
UPDATE: FDA approves Vertex Incivek for hepatitis C
Monday, May 23, 2011 - 9:40am | 78U.S. Food and Drug Administration today approved Incivek (telaprevir) to treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies....
-
Luna Innovations Announces New $7M Credit Facility
Monday, May 23, 2011 - 9:16am | 100Luna Innovations Incorporated (NASDAQ: LUNA) announced today that it has entered into a $7 million credit facility with Silicon Valley Bank. This credit facility includes a four-year term loan of $6 million and a $1 million revolving line of credit and replaces the $5 million dollar revolving...
-
Cleveland BioLabs Receives Notice of Patent Allowance From Japan for CBLB502
Monday, May 23, 2011 - 9:01am | 110Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that it has received a Notice of Allowance from the Japan Patent Office for a CBLB502 patent application. Allowed claims cover the method of protecting a mammal from radiation using flagellin or its derivatives, including CBLB502. Yakov...
-
Deutsche Bank Reports on Gilead Sciences
Monday, May 23, 2011 - 8:37am | 113Deutsche Bank commented on Gilead Sciences (NASDAQ: GILD) in a report released today. In the report, Deutsche Bank was positive in its assessment of the company. Deutsche Bank writes, "Analysis of IMS weekly scrips for the 6th week of Q2:11 indicates that GILD's HIV franchise is tracking slightly...
-
Benzinga's Top Pre-Market NASDAQ Gainers
Monday, May 23, 2011 - 8:20am | 158Identive Group Inc (NASDAQ: INVE) shares advanced 9.87% to $3.34 in the pre-market session. INVE and RFID industries signed a Value Added Reseller (VAR) agreement with NXP Semiconductors (NASDAQ: NXPI). Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) shares advanced 3.58% to $8.97 in the pre-market...
-
Benzinga's Top Upgrades
Monday, May 23, 2011 - 8:16am | 134Societe Generale upgraded BP plc (NYSE: BP) from “hold” to “buy.” BP's shares closed at $45.00 on Friday. BP's trailing-twelve-month revenue is $309.77 billion. JP Morgan upgraded CF Industries Holdings Inc (NYSE: CF) from “neutral” to “overweight.” CF's shares closed at $139.06 on Friday. CF's...
-
UPDATE: Piper Jaffray Upgrading Acorda Therapeutics
Monday, May 23, 2011 - 7:33am | 167Piper Jaffray is upgrading shares of Acorda Therapeutics (NASDAQ: ACOR) to Neutral from Underweight, and it has a $30 price target on shares. In a note to investors, Piper Jaffray writes, "With the European Medicine Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) reversing...
-
UPDATE: Jefferies Color on Metabolix PT Decrease
Monday, May 23, 2011 - 7:16am | 108Jefferies, which lowered its PT on shares of Metabolix, Inc. (NASDAQ: MBLX), is providing some color on the stock. “Metabolix priced a secondary offering of 6.2m common shares at $7.25/ share for $44.9m gross proceeds,” Jefferies writes. “A 30-day 15% over-allotment would increase the offering to...
-
Jefferies Lowers PT On Metabolix To $15
Monday, May 23, 2011 - 6:08am | 26Jefferies & Company has lowered the price target on Metabolix (NASDAQ: MBLX) from $19 to $15 and maintains its Buy rating.
-
Piper Jaffray Upgrades Acorda Therapeutics To Neutral, PT Raised To $30
Monday, May 23, 2011 - 5:48am | 28Piper Jaffray has upgraded Acorda Therapeutics (NASDAQ: ACOR) from Underweight to Neutral and has raised the price target from $21 to $30.